We are live on ! Find out more
SILK

Silk Road Medical, Inc. Common Stock

Delisted

SILK was delisted on the 16th of September, 2024.

139 hedge funds and large institutions have $1.34B invested in Silk Road Medical, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 53 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $5.17M | Put options by funds: $2.69M

8% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 49

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

9% less funds holding

Funds holding: 153139 (-14)

10% less capital invested

Capital invested by funds: $1.5B → $1.34B (-$154M)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

Holders
139
Holders Change
-14
Holders Change %
-9.15%
% of All Funds
2.34%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
53
Reduced
49
Closed
26
Calls
$5.17M
Puts
$2.69M
Net Calls
+$2.48M
Net Calls Change
-$3.13M
Name Holding Trade Value Shares
Change
Change in
Stake
AMR
101
Asset Management Resources
Massachusetts
$215K +$32.9K +905 +18%
AB
102
Amalgamated Bank
New York
$198K -$5.52K -152 -3%
Zurich Cantonal Bank
103
Zurich Cantonal Bank
Switzerland
$161K
Wells Fargo
104
Wells Fargo
California
$123K -$1.37M -37,681 -92%
Citigroup
105
Citigroup
New York
$118K +$27.5K +758 +31%
AIP
106
Ameritas Investment Partners
Nebraska
$96K
MLICM
107
Metropolitan Life Insurance Company (MetLife)
New York
$81.4K
Simplex Trading
108
Simplex Trading
Illinois
$79K +$17.9K +492 +29%
Canada Life
109
Canada Life
Manitoba, Canada
$71K
Barclays
110
Barclays
United Kingdom
$63K -$145K -3,996 -70%
AF
111
Advisornet Financial
Minnesota
$58K
US Bancorp
112
US Bancorp
Minnesota
$52K -$9.59K -264 -16%
HBW
113
Hazlett, Burt & Watson
West Virginia
$47K
TRCT
114
Tower Research Capital (TRC)
New York
$45K +$30.7K +844 +206%
Nisa Investment Advisors
115
Nisa Investment Advisors
Missouri
$38K +$38.1K +1,050 New
DWP
116
Destiny Wealth Partners
Florida
$36K +$36.3K +1,000 New
HS
117
Horan Securities
United States
$34K
UBS Group
118
UBS Group
Switzerland
$29K -$6.1K -168 -17%
Fidelity Investments
119
Fidelity Investments
Massachusetts
$19K +$6.25K +172 +51%
Group One Trading
120
Group One Trading
Illinois
$15K +$14.5K +400 New
SPIA
121
Steward Partners Investment Advisory
New York
$13K -$9.81K -270 -44%
PNC Financial Services Group
122
PNC Financial Services Group
Pennsylvania
$10K -$9.23K -254 -51%
Baillie Gifford & Co
123
Baillie Gifford & Co
United Kingdom
$9K
CAPTRUST Financial Advisors
124
CAPTRUST Financial Advisors
North Carolina
$9K +$4.29K +118 +85%
TWA
125
TCI Wealth Advisors
Arizona
$8K +$7.85K +216 New

SILK Hedge Fund Activity: Q2 2022 in Review

139 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Silk Road Medical, Inc. Common Stock (SILK) for Q2 2022, worth a combined $1.34B — down 10% from $1.5B a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of SILK and 16 opened new positions — a net loss of 10 holders — while 49 trimmed existing stakes and 53 added.

The largest buyer was Deerfield Management, adding an estimated $19M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $11.9M sold.

  • 139 institutional investors held Silk Road Medical, Inc. Common Stock (SILK) as of Q2 2022, down from 153 in Q1 2022.
  • Funds reported $1.34B of Silk Road Medical, Inc. Common Stock stock for Q2 2022, down 10% quarter-over-quarter.
  • 16 funds opened new Silk Road Medical, Inc. Common Stock positions in Q2 2022 and 26 closed out, a net change of -10 holders.
  • The largest Silk Road Medical, Inc. Common Stock buyer in Q2 2022 was Deerfield Management, an estimated $19M added.
  • The largest Silk Road Medical, Inc. Common Stock seller in Q2 2022 was Balyasny Asset Management, an estimated $11.9M sold.

Based on aggregated 13F filings for Q2 2022.